NL-OMON43199
Completed
Not Applicable
Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation: AfterDmab - After Dmab
ConditionsOsteoporosis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Osteoporosis
- Sponsor
- eids Universitair Medisch Centrum
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Postmenopausal women with osteoporosis (T\-score \<\-2\.5\) who reached a T score of \>\-2\.5 on the LS spine and/or Fn Neck while on treatment with denosumab attending the outpatient clinic and willing to participate.
Exclusion Criteria
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:;i) secondary osteoporosis; ii) diseases that could affect bone metabolism other then osteoporosis; iii) medications that could affect bone metabolism; iv) history of any antiosteoporotic treatment other than denosumab prior to randomization.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study to investigate changes in BMD of the lumbar spine (LS) one year after treatment discontinuation in denosumab-treated women and in denosumab-treated women who received a single infusion of zoledronic acid after treatment discontinuation.EUCTR2016-000852-91-NLeiden University Medical Center75
Active, not recruiting
Phase 1
Zoledronic acid for prevention of bone loss after bariatric surgeryMorbid obese subjects undergoing bariatric surgeryTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2019-001650-26-DKHospital South West Jutland70
Not yet recruiting
Phase 4
Zoledronic acid to improve low bone mineral density in non-ambulatory adults with cerebral palsycerebral palsyosteoporosisMusculoskeletal - OsteoporosisNeurological - Other neurological disordersACTRN12615001048572Anne Trinh40
Completed
Phase 3
Zoledronic Acid in Acute Spinal Cord InjurySpinal Cord InjuryNCT01642901Thomas Jefferson University16
Unknown
Phase 2
Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS)Bone LossMuscle AtrophyBariatric SurgeryNCT04742010Stinus Gadegaard Hansen60